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OBJECTIVE — The purpose of this study was to compare mortality risks of patients with
Charcot arthropathy with those of patients with diabetic foot ulcer and those of patients with
diabetes alone (no ulcer or Charcot arthropathy).
RESEARCHDESIGNANDMETHODS — Aretrospectivecohortof1,050patientswith
incident Charcot arthropathy in 2003 in a large health care system was compared with patients
with foot ulcer and those with diabetes alone. Mortality was determined during a 5-year fol-
low-up period. Patients with Charcot arthropathy were matched to individuals in the other two
groups using propensity score matching based on patient age, sex, race, marital status, diabetes
duration, and diabetes control.
RESULTS — During follow-up, 28.0% of the sample died; 18.8% with diabetes alone and
37.0% with foot ulcer died compared with 28.3% with Charcot arthropathy. Multivariable Cox
regression shows that, compared with Charcot arthropathy, foot ulcer was associated with 35%
highermortalityrisk(hazardratio1.35[95%CI1.18–1.54])anddiabetesalonewith23%lower
risk (0.77 [0.66–0.90]). Of the patients with Charcot arthropathy, 63% experienced foot ulcer-
ationbeforeoraftertheonsetoftheCharcotarthropathy.StratiﬁedanalysessuggestthatCharcot
arthropathy is associated with a signiﬁcantly increased mortality risk independent of foot ulcer
and other comorbidities.
CONCLUSIONS — Charcot arthropathy was signiﬁcantly associated with higher mortality
risk than diabetes alone and with lower risk than foot ulcer. Patients with foot ulcers tended to
haveahigherprevalenceofperipheralvasculardiseaseandmacrovasculardiseasesthanpatients
withCharcotarthropathy.Thisﬁndingmayexplainthedifferenceinmortalityrisksbetweenthe
two groups.
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C
harcot arthropathy is a severe joint
disease in the foot that can result in
fracture,permanentdeformity,limb
loss,andothermorbidities(1,2).Itoccurs
in individuals with diabetes complicated
by neuropathy and is known to have dra-
matic negative effects on physical func-
tion and on social, emotional, and mental
health (3). However, the mortality impli-
cations associated with Charcot arthrop-
athy are not clear.
Two previous studies reported low
mortality among patients with this condi-
tion (4,5). In contrast, Gazis et al. (6) re-
cently reported a high mortality among
47 patients treated in a specialty clinic.
Forty-ﬁve percent of patients with Char-
cot arthropathy died after a mean fol-
low-upof3.7yearscomparedwith34.0%
of those with a neuropathic foot ulcer
during the same period. Because foot ul-
cer is a known mortality risk factor (7,8),
this ﬁnding suggests that Charcot ar-
thropathy is also associated with in-
creased mortality risk.
The objective of this study was to ex-
amine whether Charcot arthropathy is as-
sociated with increased mortality risks.
Because many patients with Charcot ar-
thropathyexperiencefootulcersometime
before or after its onset, it is not clear how
muchoftheelevatedmortalityriskcanbe
attributed to Charcot arthropathy and
how much to foot ulcer or other diabetes
complications.Inthisstudy,wewillcom-
paremortalityrisksofpatientswithChar-
cot arthropathy with those of patients
withdiabetesalone(e.g.,withoutCharcot
arthropathy or foot ulceration) and with
those of patients with a foot ulcer to ex-
amine whether Charcot arthropathy in-
creases mortality risk, controlling for foot
ulcer, diabetes severity, other diabetes
complications, and comorbidities.
RESEARCH DESIGN AND
METHODS— The institutional re-
view board at the Edward Hines, Jr., VA
Hospital approved the study including a
Health Insurance Portability and Ac-
countability Act (HIPAA) waiver of
authorization.
The Department of Veterans Affairs
(VA) inpatient and outpatient datasets
for ﬁscal year 2003 (October 2002–
September 2003; all years henceforth are
ﬁscal years) were used to identify diabetic
patients. A patient in this study was de-
ﬁned as having diabetes if he or she ﬁlled
a prescription for a diabetes medication
(insulin or oral hypoglycemic agent) in
the current year and/or had two or more
hospitalizationsoroutpatientvisitswitha
diabetes code (ICD-9-CM 250.xx) over a
24-month period (9).
Identiﬁcation of case patients and
control subjects
We used a retrospective cohort design to
compare mortality risks of patients with
Charcot arthropathy with those of pa-
tientswithadiabeticfootulcer(DFU)and
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Center for Management of Complex Chronic Care, Hines VA Hospital, Hines, Illinois; the
2Institute for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, Illi-
nois; the
3Surgical Service, Hines VA Hospital, Hines, Illinois; the
4Department of Orthopaedic Surgery,
Loyola University Stritch School of Medicine, Maywood, Illinois; the
5Surgical Service, Podiatry Division,
Carl T. Hayden VA Medical Center, Phoenix, Arizona; and the
6Department of Medicine, Loyola Univer-
sity Stritch School of Medicine, Maywood, Illinois.
Corresponding author: Min-Woong Sohn, min-woong.sohn@va.gov.
Received 15 September and accepted 30 January 2009.
Published ahead of print at http://care.diabetesjournals.org on 5 February 2009. DOI: 10.2337/dc08-1695.
This article presents the ﬁndings and conclusions of the authors; it does not necessarily represent the
Department of Veterans Affairs or Health Services Research and Development Service.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
ORIGINAL ARTICLE
816 DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009diabetes alone control subjects. The over-
all VA diabetic population was ﬁrst di-
vided into three mutually exclusive
groups.Theﬁrstincludedonlypatientsin
whomCharcotarthropathywasnewlydi-
agnosed in 2003. A Charcot arthropathy
diagnosis was determined by an ICD-
9-CM diagnostic code 713.5 in any VA
inpatient and/or outpatient records.
The second group consisted of patients
in whom a DFU was newly diagnosed in
2003 but who had not experienced Char-
cot arthropathy in 2002–2007. A DFU
was identiﬁed by ICD-9-CM diagnostic
codes 707.1x or 707.9 in any patient
records. These are the two codes used in
theVAComputerizedPatientRecordSys-
tem for DFU: 707.1x is used when the
speciﬁc site of ulceration can be deter-
mined and 707.9 is used when ulceration
is found on multiple sites on the lower
extremities. This method shows excellent
agreementwithmethodsusedinprevious
studies (10,11). For example, compared
with the Harrington method (11), this
method had 97.2% sensitivity and 99.7%
speciﬁcity with 0.93.
The third group consisted of patients
who have not had any diagnosis of either
Charcot arthropathy or DFU in 2002–
2007. For the ﬁrst two groups, a condi-
tion was determined as newly diagnosed
in 2003 if it was not found in any utiliza-
tion records in 2002.
Using propensity score matching
(12), we selected two control subjects
each from the other two groups for every
patient with Charcot arthropathy in the
ﬁrst group. One-to-two matching was
used to ensure that the study sample was
adequately powered. Propensity scores
were obtained from a logistic regression
that provided the conditional probability
of a patient developing Charcot arthrop-
athy in 2003, given the baseline covari-
ates of age, sex, race/ethnicity, diabetes
duration, and diabetes control. When
multiple control subjects with the same
propensity score were found, we se-
lected one randomly.
Identiﬁcation of mortality events
Mortality events were identiﬁed by death
dates recorded in the VA Vital Status File.
This dataset contains death dates for all
VA beneﬁciaries and is known to have ex-
tremely high completeness (98.3% of all
death dates are recorded) and accuracy
(97.6% are accurate to the exact date)
compared with death dates from the Na-
tional Death Index (13). Currently, the
VA Vital Status File contains death dates
up to April 2007. For deaths that oc-
curred between April and September of
2007, we obtained death dates from the
same data sources used for constructing
the VA Vital Status File and followed the
same algorithms in choosing the best
death date (13).
Covariates
Data for known risk factors for mortality
among diabetic individuals, including
age, sex, race, marital status, diabetes du-
ration, and coexisting conditions (1),
were obtained from inpatient and outpa-
tient records in 2003. Age indicates pa-
tient’s age at the time of study entry (see
below). Diabetes duration was measured
by the number of years a patient had had
diabetes in 2003. The longest duration
that can be ascertained for this study was
6 years. We obtained A1C measurements
from the VA Laboratory Results National
Data Extracts for 2003 for all patients in
the sample. Because of the seasonal ﬂuc-
tuations in the A1C level (14), we com-
puted a mean of all available A1C values
for each patient for use as the baseline
measure of diabetes control.
All coexisting conditions in the Elix-
hauser comorbidity method (15) were
identiﬁed from inpatient and outpatient
records. Among the 29 conditions identi-
ﬁed, we chose only those that showed sig-
niﬁcant associations with mortality.
Macrovascular complications are major
mortality risk factors in diabetes (16), and
ischemic heart disease and stroke were ad-
ditionally identiﬁed and used in multivari-
able models. Supplementary Table A1
(available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1695/DC1) shows all comorbidities
and their deﬁnitions in ICD-9-CM diag-
nostic codes.
Statistical analysis
Patients were followed from the date of
study entry until 30 September 2007 for
up to 5 years. Entry date was determined
astheﬁrstdateofdiagnosisforpatientsin
the Charcot arthropathy or DFU groups.
For the diabetes alone control group, we
used the ﬁrst date of VA health care usage
in 2003 with a diagnosis of diabetes
(250.xx)asthestudyentrydate.Thetime
to event was measured from the study en-
try date to the date of death or to 30 Sep-
tember 2007. Cox proportional hazards
models were used to test whether there
were signiﬁcant differences in mortality
risk in the three groups after controlling
for coexisting conditions. We tested the
proportional hazards assumption using
analysis of scaled Schoenfeld residuals
(17) and goodness of ﬁt using Cox-Snell
residuals (18). Baseline diabetes control
caused the models to violate the propor-
tional hazards assumption and was not
used in any Cox regression models. The
full model reported in this study satisﬁes
the assumption and shows good ﬁt with
the data.
To test whether foot ulcers experi-
enced by patients with Charcot arthropa-
thy can explain part of the mortality risk
associated with Charcot arthropathy, we
estimated two additional models. We
stratiﬁed the Charcot arthropathy group
by the presence of foot ulcer and com-
pared the mortality risks among three
groups for two strata separately. We ﬁrst
includedpatientswithoutfootulcerinthe
Charcot arthropathy group and their
matched control subjects from the other
two groups to construct a restricted sam-
ple(1,950patients).Second,weincluded
patients with foot ulcer in the Charcot ar-
thropathy group and their matched con-
trol subjects from the other two groups to
construct the second restricted sample
(3,330 patients). These two restricted
samples were analyzed with Cox propor-
tional hazard models, and their results
were compared with those from the full
sample.
The role of peripheral neuropathy in
explainingmortalityrisksofpatientswith
Charcot arthropathy and DFU has been
noted previously (6). Because all patients
with Charcot arthropathy have neuropa-
thy, we could not use it as a covariate in
any model we estimated. To check
whether neuropathy could have con-
founded our results, we conducted a sen-
sitivityanalysisbasedonasubsamplethat
included patients with DFU and neurop-
athy and their matches in the other two
groups.
RESULTS— Among the overall dia-
betic population in 2003, Charcot ar-
thropathy was newly diagnosed in 1,050
patients, DFU was newly diagnosed in
16,260whohadneverexperiencedChar-
cot arthropathy in 2002–2007, and
868,844 patients had neither Charcot ar-
thropathy nor DFU during the same pe-
riod. After 1:2 matching, there were
1,050patientsintheCharcotarthropathy
group and 2,100 patients in each of the
other two groups for a total of 5,250 pa-
tients in the study sample. The baseline
characteristics of the sample are shown in
Table 1. Three-group comparison of fac-
Sohn and Associates
DIABETES CARE, VOLUME 32, NUMBER 5, MAY 2009 817tors used in matching suggests that
matching was good.
Patient age at the time of study entry
was63yearswithaSDof9.7years.Over-
all, 40% of patients had diabetes for 6
years and 31% had an average A1C 7%
in the baseline year.
Patients with a DFU tended to have
coexisting conditions more frequently
than those in the other two groups, in-
cluding peripheral vascular disease
(PVD), congestive heart failure, ischemic
heart disease, stroke, and chronic pulmo-
nary disease.
Of 5,250 patients in the sample,
1,468 (28.0%) died during follow-up,
with 28.3, 37.0, and 18.8% mortality
rates in the Charcot arthropathy, DFU,
and diabetes alone control groups, re-
spectively. Table 2 shows unadjusted and
adjusted hazard ratios (HRs) obtained
from two Cox regression models esti-
mated from the full sample.
Compared with Charcot arthropathy,
the unadjusted mortality risk was higher
for the DFU group (HR 1.41 [95% CI
1.23–1.61]) but lower for the diabetes
alone control group (0.61 [0.53–0.72]).
HRs adjusted for comorbidities show that
the differences in mortality risks between
the Charcot arthropathy and the other
two groups were generally smaller than
the unadjusted comparisons suggest.
Compared with patients with Charcot ar-
thropathy, those with a DFU had a 35%
higher mortality risk (1.35 [1.18–1.54])
and those with diabetes alone had a 23%
lower mortality risk (0.77 [0.66–0.90]).
Among patients with Charcot ar-
thropathy, 660 (63%) experienced a foot
ulcer sometime between 2002 and 2007.
Of these, 431 (65.3%) had ulceration
concurrently with or before and 229
(34.7%) had ulceration after the onset of
Charcot arthropathy. Their unadjusted
mortality rates were higher if they had a
foot ulcer (30.2%) than if they did not
(26.9%). To estimate the contribution to
mortalityriskoffootulceramongpatients
with Charcot arthropathy, we estimated
Table 1—Baseline characteristics of patients in three comparison groups
Characteristic
Comparison groups
Charcot
arthropathy DFU
Diabetes
alone
n 1,050 2,100 2,100
Age (years) 63.0  9.6 62.8  9.8 62.7  9.6
Race (%)
Non-Hispanic white 72.8 73.8 72.7
Non-Hispanic black 11.1 11.8 11.2
Hispanic 3.1 1.9 3.2
Other or unknown 13.0 12.5 12.9
Male sex (%) 97.1 97.9 97.3
Married (%) 58.0 58.6 58.1
Diabetes duration 6 years (%) 40.9 39.8 40.9
Diabetes control (%)
A1C 7% 31.3 31.5 31.4
A1C, 7–9% 38.2 37.6 38.2
A1C 9% 15.5 15.2 15.5
A1C, unmeasured 15.0 15.8 14.9
Comorbidities (%)
Ischemic heart disease* 34.8 38.4 30.9
Stroke* 7.8 14.4 6.7
Peripheral vascular disease* 26.9 34.5 8.7
Congestive heart failure* 12.6 17.8 6.8
Chronic pulmonary disease* 9.8 14.6 11.1
Renal failure* 15.1 11.4 5.2
Cancer 4.0 4.5 5.6
Deﬁciency anemias* 17.3 13.8 5.6
Paralysis* 1.0 4.0 1.2
Other neurological disorders 3.4 3.9 2.6
Liver disease* 2.5 3.8 1.9
Coagulopathy* 1.1 2.4 1.4
Data are means  SD or %. n  5,250. *P  0.05 (two-tailed 
2 tests).
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the two restricted samples (Table 2).
Comparison of unadjusted HRs
across three samples shows that the dif-
ference in mortality risks between the
Charcot arthropathy and DFU groups is
largestintherestrictedsample1(Charcot
arthropathy without ulcer: HR 1.63
[1.30–2.04]) and smallest in the re-
stricted sample 2 (Charcot arthropathy
with ulcer: 1.30 [1.10–1.53]). On the
other hand, the difference between Char-
cot arthropathy and diabetes alone was
larger in unadjusted rates in the restricted
sample 2 (0.56 [0.46–0.67]) and smaller
in the restricted sample 1 (0.73 [0.57–
0.93]). When comorbidities were con-
trolled for in the adjusted models, HRs in
the three samples became considerably
less variable than those from unadjusted
comparisons. The adjusted HRs indicate
32–41% higher mortality risk for DFU
than for Charcot arthropathy in the three
samples. The adjusted comparisons be-
tween Charcot arthropathy and diabetes
alonecontrolgroupsshow21–24%lower
mortality risk for the latter.
Table 3 shows the model estimated
from the full sample. Mortality risks were
signiﬁcantly increased with older age,
male sex, and unmarried status. Among
comorbidities, liver disease, renal failure,
and congestive heart failure contributed
the most to the mortality risk.
We conducted sensitivity analyses.
First, we examined whether the observed
results might be different for the noneld-
erly patients (aged 65 years) with a 1:4
matched sample, and the results are
shown in supplementary Table A2 (avail-
able in an online appendix). Even though
noneoftheHRsindicatedstatisticallysig-
niﬁcant differences in mortality risk be-
tween Charcot arthropathy and DFU
groups,theoverallﬁndingsareconsistent
with the models estimated from the full
sample.
Second, we selected only patients
with peripheral neuropathy in the Char-
cot and DFU groups and compared their
mortality risks. For this comparison, we
started with the patients with foot ulcers
in whom neuropathy had ever been diag-
nosed in 2002–2007 (70%) and found
their matched pairs in the Charcot ar-
thropathy and diabetes alone control
groups. The results from a Cox regression
model (supplementary Table A3, avail-
able in an online appendix) suggest that
DFU was associated with a signiﬁcantly
higher mortality risk than Charcot ar-
thropathy among patient with neuropa-
thy (HR 1.23 [95% CI 1.06–1.43]).
CONCLUSIONS — This study shows
that patients with Charcot arthropathy or
DFU have signiﬁcantly increased mortal-
ity risk than otherwise comparable pa-
tients with diabetes alone. The mortality
risk associated with Charcot arthropathy
was confounded by the presence of a foot
ulcer; however, Charcot arthropathy has
signiﬁcantly increased mortality risk in-
dependent of foot ulcer and other diabe-
tes complications. When patients with
Charcot arthropathy without foot ulcer-
ation were compared with their matched
control subjects (restricted sample 1), the
mortality risk was 63% higher in unad-
justed rates for patients with foot ulcers.
This difference was signiﬁcantly larger
than that (30%) from the comparison be-
tween patients with Charcot arthropathy
with foot ulceration and patients with
DFUs (restricted sample 2). This result
suggests that the mortality risk in the
overall Charcot arthropathy group may
be in large part attributable to foot ulcer-
ation. Moreover, when the HRs were ad-
justed for comorbidities, they became
similar for both sets of comparisons in all
threemodels,indicatingthatvariationsin
HRsacrossthreesamplesweredueinpart
also to differences in the presence of co-
morbiditiesinthethreegroups.However,
there was still a signiﬁcantly increased
mortality risk associated with Charcot ar-
thropathy, after controlling for foot ulcer
or other diabetes complications such as
PVD, congestive heart failure, ischemic
heart disease, and renal failure.
Gazis et al. (6) reported a mortality
rate of 44.7% for patients with Charcot
arthropathy after a mean follow-up of 3.7
years, which is considerably higher than
the 5-year mortality rate of 28.3% among
our patients with Charcot arthropathy.
They further reported that the mortality
risk for Charcot arthropathy is not statis-
tically different from that for neuropathic
DFU, whereas our study shows a signiﬁ-
cant difference between the two groups
(supplementary Table A3).
Part of these differences can be ex-
plainedbythehighpercentageofpatients
with type 1 diabetes in the sample of
Gazis et al. (18%) and partly by the fact
that their sample consisted of patients
from a large specialty foot clinic who, be-
cause of selection by referral (4), were
likely to be sicker than patients in the
population-based sample used in this
study. They experienced onset of Charcot
arthropathy 4 years earlier than patients
in our sample (59 vs. 63 years), an in-
dication that they had more severe dia-
Table 3—Adjusted HR from the full Cox proportional hazards regression model
Variables* HR (95% CI) P
Comparison group Charcot arthropathy
Foot ulcer 1.348 (1.176–1.544) 0.001
Diabetes alone 0.773 (0.661–0.903) 0.001
Age (years) 1.039 (1.033–1.045) 0.001
Race non-Hispanic white
Non-Hispanic black 0.978 (0.828–1.155) 0.793
Hispanic 0.921 (0.631–1.343) 0.668
Other 0.701 (0.560–0.879) 0.002
Male female 1.562 (1.022–2.388) 0.039
Married not married 0.781 (0.703–0.868) 0.001
Diabetes 6 years 1.074 (0.966–1.193) 0.187
Ischemic heart disease 1.227 (1.096–1.374) 0.001
Stroke 1.121 (0.963–1.304) 0.141
Peripheral vascular disease 1.243 (1.107–1.397) 0.001
Congestive heart failure 1.953 (1.709–2.232) 0.001
Chronic pulmonary disease 1.268 (1.105–1.453) 0.001
Renal failure 1.840 (1.599–2.118) 0.001
Cancer 1.569 (1.295–1.901) 0.001
Other neurological disorders 1.592 (1.264–2.006) 0.001
Deﬁciency anemias 1.323 (1.152–1.519) 0.001
Paralysis 1.474 (1.106–1.965) 0.008
Liver disease 2.096 (1.623–2.706) 0.001
Coagulopathy 1.519 (1.148–2.010) 0.003
n  5,250. *Reference categories are in brackets.
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Despite these differences, both studies
show greatly increased mortality risks
for patients with either Charcot ar-
thropathy or DFU compared with those
with diabetes alone.
These ﬁndings suggest that Charcot
arthropathyandfootulcerationaremark-
ers of signiﬁcant systemic pathological
conditions in diabetic patients that in-
creases their mortality risk. The patho-
physiology of higher mortality risks
associated with these two conditions is
still largely unknown. One explanation
for foot ulcer having the highest mortality
risk among the three comparison groups
isthatthepresenceofulcerationincreases
the risk of infection, which in turn in-
creases the potential for adverse systemic
effects, multiorgan failure, and death.
However, patients with Charcot arthrop-
athy with foot ulceration did not have as
high a mortality risk as those with foot
ulceralone.Weconjecturethatulceration
due to Charcot arthropathy (	35% of all
foot ulcers experienced by patients with
Charcot arthropathy) may not have as
high a mortality risk as a DFU does in the
absence of Charcot arthropathy. These
are mostly complications arising from the
mismatch between protective footwear
anddevelopmentoffootdeformitiessuch
as protruding bones (5). The resulting
secondary ulceration may be more local
than systemic in etiology and hence be
associated with a lower mortality risk
than a typical DFU. Further, ongoing
treatment of Charcot arthropathy might
have led to earlier diagnosis and active
treatmentofbothconcurrentandsecond-
ary foot ulcers.
Clinically, our ﬁndings suggest that
early identiﬁcation and vigilant care of
Charcot arthropathy and foot ulcer are
important not only for treating these con-
ditions but also for reducing mortality
risks associated with them. DFU is often
difﬁcult to diagnose early because of pe-
ripheral neuropathy and lack of local and
systemic signs of infection (19), making
quarterly foot screening and patient edu-
cation for daily foot examinations and
self-care imperative for these high-risk
patients.
Given that DFUs have greater mortal-
ity risks than some cancers such as pros-
tate cancer, breast cancer, or Hodgkin’s
disease(20),themortalityriskneedstobe
communicated to the patients as early as
possible so that they can assume a more
active role in medical management of
DFUs than they do now (21). Coexisting
conditions such as cardiovascular and re-
nal diseases need to be aggressively man-
aged along with foot care.
This study has several limitations.
The ﬁrst is that it relied on inpatient and
outpatient records collected for adminis-
trativepurposes.Althoughadministrative
records were supplemented by extensive
pharmacydataandlaboratorytestresults,
the accuracy of these records needs to be
considered when the study results are in-
terpreted. A study of Department of Vet-
erans Affairs (VA) disease coding in the
administrative databases reported that
diseases were generally coded accurately
butthattherewerealsolargevariationsin
accuracyfromdiseasetodisease(22).An-
other study reported an extremely high
accuracyofacutemyocardialinfarctionat
96% sensitivity (23). Other conditions
may not have been coded as accurately.
PVDcodingaccuracyintheVAdataisnot
well-known, but given the 60% sensitiv-
ityofcodingforPVDintheMedicaredata
(24) and the fact that many patients have
undiagnosed and/or asymptomatic PVD,
the ﬁndings about PVD should be inter-
preted with caution.
Second, comorbidity measures were
obtained from the baseline year and may
not account for occurrences in the three
groups after the baseline year. In a supple-
mental analysis, we assessed whether a pa-
tient in the sample had congestive heart
failure in 2003–2007 and used this infor-
mation in a multivariable model instead of
the baseline measure. The results from this
model were remarkably consistent with
those from the baseline model. The reason
may be that congestive heart failure is a
chronic condition that persists through the
patient’s life span. All other comorbidities
were also chronic in nature.
Third, we did not have access to data
for Medicare usage by elderly veterans. A
supplemental analysis showed that, com-
pared with the number of VA users with
diabetes estimated from the 2003 Behav-
ioral Risk Factor Surveillance System na-
tional survey, almost 98% of all VA users
with diabetes could be identiﬁed through
VA inpatient and outpatient records
alone. Nonetheless, there might have
been some VA users who received diabe-
tes care from Medicare providers where
Charcot arthropathy, foot ulcer, other di-
abetes complications, or comorbidities
were diagnosed. To the extent that these
conditionswerenotalsodiagnosedbyVA
physicians, they might have affected our
ﬁndings.However,thesensitivityanalysis
with patients aged 65 years (supple-
mentary Table A2) suggests that the un-
observed medical conditions listed in the
Medicare data did not systematically bias
the results.
Insummary,tothebestofourknowl-
edge, this is the ﬁrst study to compare
mortalityrisksamongpatientswithChar-
cot arthropathy, foot ulceration, and dia-
betes without these complications. A
previous study by Pinzur and Evans (3)
noted that Charcot arthropathy was asso-
ciated with poor quality of life, frequent
disability,andprematureretirementfrom
theworkforce.Ourstudyfurthersuggests
that it is also associated with increased
mortality risk. These ﬁndings accentuate
the need for early detection of Charcot
arthropathy to limit the disease progres-
sion and to reduce the risk of foot ulcer-
ation and death.
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